The European Commission (EC) has granted a €6m grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501. The FIGHT HLH consortium lead by NovImmune ...
German-based Evotec has partnered with Probiodrug to advance the development operations of drugs targeting major age related diseases such as Alzheimer's disease(AD). Evotec will support the pre-clinical and clinical development of ...
Tags: Alzheimer's disease, Evotec, glutaminyl cyclase, neurodegeneration
TG Therapeutics and Rhizen Pharmaceuticals have collaborated to develop and commercialise Rhizen PI3K delta inhibitor, TGR-1202 previously referred as RP5264. As part of the collaboration, the companies will develop TGR-1202 on a ...
Nectid, a drug discovery company, has initiated clinical development of agomelatine for autism and pain indications in the US. Agomelatine, a melatonergic agonist (MT1 and MT2 receptors) and 5-HT2C antagonist, is approved for the ...
Kaketsuken, also known as the Chemo-Sero-Therapeutic Research Institute, has become the first Japanese pharmaceutical company to use the combined capabilities of the Medidata Balance and Medidata Rave for a Japanese clinical trial. ...
The SFJ Pharmaceuticals Group (SFJ) has partnered with Pfizer to co-develop Dacomitinib as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of epidermal ...
Tags: Cancer Drug, cell lung cancer, therapy
Theravance has entered into a research partnership with Merck, known as MSD outside the US and Canada, for the development of potential cardiovascular therapeutics to treat hypertension and heart failure. As per the agreement, Merck will ...
Tags: Cardiovascular Therapeutics, Theravance, Merck, MSD
Pfizer and Protalix BioTherapeutics have announced FDA approval of Elelyso (taliglucerase alfa) for injection to treat type 1 Gaucher disease. Elelyso, derived from ProCellEx, is an enzyme replacement therapy (ERT) for the long-term ...
Tags: Protalix/Pfizer Gaucher Drug, Pfizer and Protalix BioTherapeutics
The European Commission (EC) has granted marketing authorization for Meda's Zyclara (imiquimod 3.75% cream) for the treatment of actinic keratosis (AK), in the European Union. Zyclara can detect and eliminate subclinical as well as ...
Tags: Meda Zyclara, actinic keratosis, clinical AK lesions, Skin cancer
Baxter International has collaborated with Chatham Therapeutics for the development and commercialization of factor IX hemophilia B gene therapy treatment. According to the agreement, the companies will investigate the next generation of ...
Tags: IX hemophilia B gene therapy, Biological Nano Particles, clinical trials
Biogen Idec (BIIB) and Isis Pharmaceuticals have entered into an exclusive, worldwide option and collaboration agreement, pursuant to which the companies will develop and commercialize a novel antisense drug for the treatment of myotonic ...
Tags: Steinert Disease, antisense drug
Shire and Boston Children's Hospital have formed a three-year, broad research collaboration to develop new therapies to treat rare pediatric diseases. As part of the agreement, Shire will make an initial upfront payment to Boston ...
Tags: pediatric diseases, Children's Hospital, new therapies
Nestlé is extending its Product Technology Centre (PTC) in Konolfingen, as part of its commitment to increase its research and development (R&D) capabilities in Switzerland. Earlier this year, the company opened a Clinical ...
Tags: Nestlé, Capabilities, Switzerland
Galapagos has identified new class of antibiotics targeting drug resistant Staphylococcus aureus (MRSA) strains and commenced clinical development of first antibiotic. The selected candidate, CAM-1, was effective against all tested MRSA ...
Tags: antibiotics targeting drug, MRSA
XTL Biopharmaceuticals has acquired 4,620,356 shares of Proteologics from Teva Pharmaceutical for nearly NIS6.5m($1.6m). The company has purchased single share at an amount of NIS1.405($0.36). The acquired shares represent all the ...
Tags: XTL Biopharmaceuticals, shares, drugs, multiple myeloma, schizophrenia